Gene-Disorder Association · Article
Gene
KMT2ALysine Methyltransferase 2A
×
First reported
1996
Supporting publications
6
Manually curatedApproved treatment annotated
Association Review
In brief
The association between KMT2A (Lysine Methyltransferase 2A) and Myelodysplastic Syndrome is reported, with clinical genetic testing available.
Sources
1
Clinical variants
0
Symptoms
1
Compounds
1
Trials
116of 410 via KMT2A compounds
Publications
6
01
At a glance
Association overview
A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
Request access
02
Provenance
Evidence and sources
1 source
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
Request access
2 source summaries
A gene summary alongside the source descriptions it was distilled from.
Request access
04
Myelodysplastic Syndrome
The disorder
11 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
Request access
05
Phenotype
Clinical features
1 clinical feature
The disorder’s clinical features (HPO) grouped by body system, each with observed frequency and penetrance.
Request access
06
Interventions
Therapeutics
1 compound or drug
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
Request access
07
Human studies
Clinical trials
410 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
Request access
6 publications
Publications linking the gene and the disorder, with title, authors, journal, year and citation metrics.
Request access
09
Provenance
References & sources
12 references
Every source and publication cited across this dossier, as one numbered reference list.
Request access